Pegylated interferon alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients
Callens, Stevena,b; Bottieau, Emmanuela,b; Michielsen, Peterc; Colebunders, Roberta,b
aDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium; bTropical Diseases Unit and cDepartment of Gastroenterology, University Hospital, Antwerp, Belgium.
See also pp. 1, 59, 67, 75, 121
Received: 6 June 2003; accepted: 11 August 2003.
Pérez-Olmeda et al.  reported that pegylated interferon alfa-2b (peg-IFN) plus ribavirin therapy cured one third of patients co-infected with HIV and hepatitis C virus (HCV), and that such therapy is relatively well-tolerated. In only two out of the 68 patients (3.1%) was a decline in the absolute CD4 lymphocyte count greater than 33% observed. In none of them was a change in the CD4 lymphocyte percentage seen.
We recently observed an HIV–HCV co-infected patient treated with peg-IFN/ribavirin in which the CD4 lymphocyte count fell from 0.429 × 109/l (28.1%) to 0.029 × 109/l (9%). These low levels persisted despite a sustained undetectable HIV viral load, even after the HCV therapy was stopped.
A 49-year-old, HIV–HCV co-infected man, with compensated liver cirrhosis (Child–Pugh class A) was started on peg-IFN (1.50 μg/kg per week) and ribavirin (1200 mg once a day). His body weight was 100 kg. For HIV infection he was treated with abacavir, lamivudine and zidovudine. At the start of the peg-IFN/ribavirin treatment his CD4 lymphocyte count was 0.429 × 109/l (28.1%) and his viral load was less than 50 copies/ml plasma. Two months after the initiation of the peg-IFN/ribavirin, he developed anaemia (haemoglobin 9.5 g/dl) and thrombocytopenia (40 × 109 /l). For this reason the HCV treatment was continued at a reduced dosage (peg-IFN 100 μg a week, ribavirin 600 mg once a day). Ultimately, both drugs had to be discontinued after 12 weeks when severe anaemia developed (haemoglobin 7.4 g/dl). The HCV-RNA (polymerase chain reaction test) level at that time was negative. One month later when the haemoglobin level was 8.7 g/dl and the platelet count was 99 × 109 /l, peg-IFN monotherapy was restarted. After the reintroduction of peg-IFN, a severe Coombs-positive anaemia developed (haemoglobin 5.1 g/dl) and thrombocytopenia persisted (72 × 109 /l). Zidovudine was switched to stavudine and the peg-IFN was stopped. His CD4 lymphocyte count at that time was 0.275 × 109/l (28.1%). Finally, high-dose steroid therapy reversed the anaemia and thrombocytopenia, but the patient developed diabetes mellitus requiring insulin therapy. His CD4 lymphocyte count fell during peg-IFN therapy, and continued to decline to a level of 0.029 × 109 cells/l (9.0%) 3 months after this therapy was stopped. Ten months after the start of the peg-IFN/ribavirin therapy the patient died as a result of invasive pulmonary aspergillosis.
Interferon potentially induces haemolytic anaemia, thrombocytopenia, leucopenia with neutropenia and a decrease in the CD4 lymphocyte cell count [2–4]. This decrease in the CD4 lymphocyte count during interferon therapy has been attributed to autoimmunity [5,6]. Generally, a spontaneous recovery in the CD4 lymphocyte count is observed after stopping interferon treatment. However, in our patient, despite a sustained undetectable HIV viral load, his CD4 lymphocyte count continued to drop after the termination of HCV therapy.
The decision to discontinue peg-IFN/ribavirin treatment because of haematological toxicity, in HIV–HCV co-infected patients should be made sufficiently early, in order to avoid a prolonged low CD4 lymphocyte count and an increased risk of developing opportunistic infections.
1. Pérez-Olmeda M, Núñez M, Romero M, Gonzalez J, Castro A, Arribas JR, et al
. Pegylated IFN-a2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS
2. Fried M, Shiffman M, Reddy R, Smith C, Marinos G, Goncales FL Jr, et al
. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med
3. Cotler SJ, Jensen DM. Treatment of hepatitis C virus and HIV co-infections. Clin Liver Dis
4. Rockstroh JK, Mudar M, Lichterfeld M, Nischalke HD, Klausen G, Gölz, J, et al
. Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients. AIDS
5. Vento S, Di Perri G, Cruciani M, Garofano T, Concia E, Bassetti D. Rapid decline of CD4+ cells after alpha-interferon treatment in HIV-1 infection. Lancet
6. Soriano V, Bravo R, Samaniego JG, Gonzalez J, Odriozola PM, Arroyo E, et al
. CD4+ T-lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C. AIDS
This article has been cited 3 time(s).
Acta Gastro-Enterologica Belgica
Treatment of chronic hepatitis C in patients with human immunodeficiency virus (HIV) with weekly peginterferon alpha-2b plus ribavirin : a multi-centred Belgian study
Acta Gastro-Enterologica Belgica, 72(4):
Acta Gastro-Enterologica Belgica
Therapy of chronic hepatitis C in the setting of HIV co-infection
Acta Gastro-Enterologica Belgica, 68(1):
Chinese Medical JournalHuman immunodeficiency virus and hepatitis C virus co-infection: epidemiology, natural history and the situation in ChinaChinese Medical Journal
© 2004 Lippincott Williams & Wilkins, Inc.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Data is temporarily unavailable. Please try again soon.